🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07002034
Recruiting Phase 2

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034 · tracked via the Priya Life Science USA tracker
Sponsor
Reunion Neuroscience Inc
Phase
Phase 2
Started
2025-07-30
Last updated
2026-09-15

Condition(s) studied

Adjustment Disorder

Investigational drug(s) / intervention(s)

RE104 for Injection

RE104 for Injection: Single, subcutaneous dose of RE104 for Injection

Study summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview with evidence that the AjD was instigated by one of the following medical illnesses (e.g., diagnosis, impact, management, recurrence, prognosis): Cancer, ALS, MS, PD or IPF * Is sufficiently ambulatory and capable of self care as necessary to complete study procedures * Has normal cognitive function * Is on stable use of antidepressants or psychotherapy, or is willing to delay use until the end of study * If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant * Is willing and able to comply with the conditions and requirements of the study Exclusion Criteria: * Has a significant risk of suicide * Has active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder * Has active or a history of central nervous system malignancy * Has other medically significant conditions rendering unsuitability for the study * Has used or will need to use prohibited medications or therapies * Has a known sensitivity or intolerance to study intervention or potential rescue medications

Primary outcome measure(s)

Trial sites (32)

FacilityCityRegionStatus
UAB, Psychiatry and Behavioral Neurology Birmingham Alabama Recruiting
University of Arizona Tucson Arizona Recruiting
Kadima Neuropsychiatry Institute San Diego California Recruiting
Providence Medical Foundation Santa Rosa California Recruiting
University of Colorado Aurora Colorado Recruiting
University of South Florida, Department of Psychiatry and Behavioral Neuroscience Tampa Florida Recruiting
Emory University Atlanta Georgia Recruiting
Hawaii Pacific Neuroscience Honolulu Hawaii Recruiting
Rush University Medical Center Chicago Illinois Recruiting
University of Chicago Medical Center Chicago Illinois Recruiting
The University of Kansas Medical Center Kansas City Kansas Recruiting
LSU Health Shreveport Shreveport Louisiana Recruiting
Sunstone Therapies, PC Rockville Maryland Recruiting
Sheppard Pratt Towson Maryland Recruiting
Dana Farber Cancer Institute Boston Massachusetts Recruiting
University of Massachusetts Chan Medical Center Worcester Massachusetts Recruiting
University of Michigan Ann Arbor Michigan Recruiting
Henry Ford Health Novi Michigan Recruiting
University of Nebraska Medical Center Omaha Nebraska Recruiting
University of New Mexico, School of Medicine Albuquerque New Mexico Recruiting
Roswell Park Center Institute Buffalo New York Recruiting
NYU Langone Health New York New York Recruiting
University of North Carolina at Chapel Hill Chapel Hill North Carolina Recruiting
Cleveland Clinic Cleveland Ohio Recruiting
The Ohio State University, Department of Psychiatry Columbus Ohio Recruiting
University of Pennsylvania Philadelphia Pennsylvania Recruiting
Alliance for Multispecialty Research Clinical Knoxville Tennessee Recruiting
Dell Medical School, University of Texas at Austin Austin Texas Recruiting
Cedar Clinical Research Inc. Draper Utah Recruiting
UVA Center for Psychiatric Clinical Research Charlottesville Virginia Recruiting
Seattle Neuropsychiatric Treatment Center Seattle Washington Recruiting
University of Wisconsin at Madison Madison Wisconsin Recruiting

More Reunion Neuroscience Inc trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07002034 on ClinicalTrials.gov ↗ ← All trials in the USA